Search details
1.
Peripheral T cell expansion predicts tumour infiltration and clinical response.
Nature
; 579(7798): 274-278, 2020 03.
Article
in English
| MEDLINE | ID: mdl-32103181
2.
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy.
Cell Rep Med
; 4(1): 100878, 2023 01 17.
Article
in English
| MEDLINE | ID: mdl-36599350
3.
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
Cancer Cell
; 38(6): 803-817.e4, 2020 12 14.
Article
in English
| MEDLINE | ID: mdl-33157048
4.
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Nat Med
; 26(5): 693-698, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32405063
5.
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Nat Med
; 24(12): 1941, 2018 Dec.
Article
in English
| MEDLINE | ID: mdl-30291359
6.
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Nat Med
; 24(6): 749-757, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29867230
7.
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Nat Med
; 27(3): 560, 2021 Mar.
Article
in English
| MEDLINE | ID: mdl-33547461
Results
1 -
7
de 7
1
Next >
>>